同仁堂科技披露的半年业绩显示，在其产品矩阵中，六味地黄丸领衔的泌尿补肾大品种集群表现亮眼， 六味地黄丸系列产品销售收入较上年同期增长约47.99%。在其带动下，金匮肾气丸系列销售收入同比 增长19.55%，壮腰健肾丸系列、知柏地黄丸系列及归芍地黄丸系列等产品的销售收入均较上年同期实 现双位数的增长。 围绕六味地黄丸、金匮肾气丸、壮腰健肾丸等品种，企业还依据产品特性制定差异化推广策略，布局微 博、抖音、小红书等深受年轻用户喜爱的平台，通过"线上+线下"联动营销，实现了市场占有率大幅度 提升。 今年下半年，同仁堂科技将持续强化品种培育，精准施策大品种集群矩阵建设，通过核心单品精准卡 位、渠道精细化建设，驱动业绩高质量增长。 而同仁堂"配方独特、选料上乘、工艺精湛、疗效显著"的制药特色则这一品种提供了有力支撑，企业将 药材鉴别、炮制、制药环节中的多项"非遗"技艺与现代工艺相结合，开发了水蜜丸、大蜜丸、软胶囊、 浓缩丸等剂型，满足不同群体、不同场景的用药需求。 同仁堂科技旗下六味地黄丸领衔的泌尿补肾大品种集群，还拥有知柏地黄丸、杞菊地黄丸、归芍地黄 丸、金匮肾气丸等众多明星产品，能够针对肾阴虚火旺、肝肾阴虚、肾阳虚等 ...

Core Viewpoint The Guangdong Jiaying Pharmaceutical Co., Ltd. is preparing for its 2024 Annual General Meeting, focusing on various proposals including financial reports, profit distribution plans, and corporate governance matters. Group 1: Meeting Details - The meeting is scheduled for May 16, 2025, at 14:30 in Meizhou, Guangdong Province [5] - Attendees will include shareholders, company directors, supervisors, senior management, and invited guests [5] Group 2: Proposals for Review - Proposal 1: Review of the 2024 Annual Report and its summary [6] - Proposal 2: Review of the 2024 Financial Settlement Report, audited by Zhonghua Accounting Firm [7] - Proposal 3: Profit distribution plan for 2024, which proposes no cash dividends or stock bonuses [9][11] - Proposal 4: Review of the 2024 Board of Directors' Work Report, highlighting operational achievements and challenges [14] - Proposal 5: Review of the 2024 Supervisory Board's Work Report, detailing compliance and oversight activities [32] - Proposal 6: Confirmation of 2024 director remuneration and proposal for 2025 remuneration [36] - Proposal 7: Request for a comprehensive credit limit of up to RMB 200 million from banks for operational needs [37] - Proposal 8: Review of daily related party transactions for 2024 and projections for 2025 [40] Group 3: Financial Performance and Strategy - The company reported a net profit of RMB 16,346,842.23 for 2024, with no cash dividends proposed due to financial constraints and strategic investments [9][11] - The company aims to enhance its product portfolio and reduce reliance on a single product line, particularly in response to market fluctuations affecting its main products [11][12] - The company plans to invest in research and development to diversify its offerings and improve market competitiveness [29][30] Group 4: Corporate Governance and Compliance - The company has established a robust internal control system to ensure compliance with laws and regulations, maintaining transparency and protecting shareholder interests [33][35] - The Supervisory Board has actively monitored the company's operations, ensuring adherence to legal and regulatory standards [32][34]

Core Viewpoint - The company, Jiajing Pharmaceutical, has shown significant improvement in its financial performance, achieving both revenue and profit growth in the first quarter of 2025, driven by cost reductions and increased sales volume [2][3]. Financial Performance - In Q1 2025, Jiajing Pharmaceutical reported revenue of 122 million yuan, a year-on-year increase of 28.83%, effectively halting six consecutive quarters of revenue decline [3] - Net profit surged by 197.23% to 15.75 million yuan, marking two consecutive quarters of profitability [3] - The sales gross margin reached 66.81%, the highest since 2022, attributed to revenue growth and improved product gross margins [3] Cost Structure and Raw Material Prices - The improvement in gross margin is primarily due to a decline in raw material prices, with the Chinese herbal medicine price index dropping by 10% year-on-year in Q1 2025 [4] - Key raw materials for Jiajing Pharmaceutical's core product, Shuangliao Houfeng San, have seen price reductions exceeding 30% since their peak in 2024 [7] - Raw material costs account for over 60% of the company's total costs, and the recent price declines have alleviated cost pressures significantly [7] Operational Efficiency - The company has enhanced its production efficiency through automation and improved production processes, which have lowered production costs [8] - Jiajing Pharmaceutical has implemented refined operations to ensure product profitability, focusing on quality management and efficient production planning [8] Product Portfolio and Market Strategy - Jiajing Pharmaceutical is focusing on two main product categories: throat and orthopedic products, with a strategy to develop best-selling products and accelerate new product launches [10][12] - The company has a diverse product lineup, including 70 approved drug varieties, with core products like Shuangliao Houfeng San and Jiekou Qili series accounting for over 66% of revenue [10] Strategic Partnerships and Market Expansion - The acquisition of a 7% stake by Yangtianhe has improved Jiajing Pharmaceutical's market coverage and sales channels, leveraging Yangtianhe's extensive retail network [15] - The collaboration aims to create a dual-driven model of "pharmaceutical commerce + pharmaceutical industry," enhancing resource sharing and market reach [15] - Jiajing Pharmaceutical plans to strengthen partnerships with major retail chains and expand its online sales channels to increase market share [17]